Article Text

other Versions

Download PDFPDF
1-Hexyl n-cyanoacrylate compound (Neucrylate AN), a new berry aneurysm treatment. I. Theoretical basis and laboratory evaluation
  1. Charles W Kerber,
  2. Ramin Sean Pakbaz
  1. Departments of Radiology and Neurosurgery, UCSD Medical Center, San Diego, California, USA
  1. Correspondence to Dr C W Kerber, UCSD Medical Center, 200 W Arbor Dr, San Diego, CA 92103-8756, USA; cwkerber{at}gmail.com

Abstract

Purpose To develop and optimize a system for treating cerebral berry aneurysm using a new polymer based liquid embolic agent.

Materials and methods Using a variety of human corrosion casting aneurysm replicas placed in a circuit of pulsatile flowing blood, techniques were developed to optimize aneurysm filling and recreate good blood flow dynamics. As part of this effort, both experienced physicians and lay personnel were asked to treat these replicas to discover common failure modes. Additional surgically created aneurysms in dog carotid arteries were treated by experienced physicians.

Results Physicians experienced in the use of microcatheters and endovascular techniques learned to use the device effectively after, on average, five aneurysm treatments. In the dog aneurysms, all were treated to complete filling.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Competing interests Charles Kerber MD is a shareholder and chief medical officer in Valor Medical Inc. Ramin Sean Pakbaz is a shareholder in Valor Medical Inc. There are no other competing interests

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles